Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012. The Breakthrough Designation is granted to […]readmore
Tags : Nektar
Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb Published: Jan 10, 2020 | Tags: Nektar Therapeutics, Signs, Clinical Trial, Collaboration, Bristol-Myers Squibb 2. Eli Lilly to Acquire Dermira for […]readmore
The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list […]readmore
Shots: The FDA’s BT designation is based on ongoing P-I/II PIVOT-02 study assessing the doublet therapy in patients with metastatic melanoma. FDA’s BT designation is to expedite the development of […]readmore
Shots: The companies entered into a clinical collaboration for evaluating BioXcel’s BXCL701, Nektar’s NKTR-214 & Avelumab (co-developed and co-commercialized by Merck KGaA and Pfizer) as a triple combination therapy for […]readmore